XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Financial Statement Details (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory

Inventory consists of the following (in thousands):

 

 

 

September 30, 2023

 

 

December 31, 2022

 

Raw materials

 

$

1,918

 

 

$

2,575

 

Work-in-process

 

 

12,291

 

 

 

10,749

 

Finished goods

 

 

921

 

 

 

5,878

 

Total inventory, net

 

$

15,130

 

 

$

19,202

 
Schedule of Other Current Assets

Other current assets consist of the following (in thousands):

 

 

 

September 30, 2023

 

 

December 31, 2022

 

Prepaid research and development expenses

 

$

2,014

 

 

$

7,398

 

Non-trade receivables and other

 

 

1,226

 

 

 

2,423

 

Other prepaid expenses

 

 

5,793

 

 

 

5,987

 

Total other current assets

 

$

9,033

 

 

$

15,808

 

 
Schedule of Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

 

 

 

September 30, 2023

 

 

December 31, 2022

 

Building and leasehold improvements

 

$

42,641

 

 

$

74,889

 

Computer equipment and computer software

 

 

24,586

 

 

 

26,205

 

Manufacturing equipment

 

 

25,352

 

 

 

25,052

 

Laboratory equipment

 

 

14,592

 

 

 

24,243

 

Furniture, fixtures and other

 

 

533

 

 

 

4,263

 

Depreciable property, plant and equipment at cost

 

 

107,704

 

 

 

154,652

 

Less: accumulated depreciation

 

 

(88,243

)

 

 

(124,731

)

Depreciable property, plant and equipment, net

 

 

19,461

 

 

 

29,921

 

Construction in process

 

 

488

 

 

 

2,530

 

Property, plant and equipment, net

 

$

19,949

 

 

$

32,451

 
Schedule of Goodwill

The following is a reconciliation of the changes in our goodwill for the nine months ended September 30, 2023 (in thousands):

 

 

 

Nine months ended September 30, 2023

 

Goodwill – beginning balance

 

$

76,501

 

Impairment of goodwill

 

 

(76,501

)

Goodwill – ending balance

 

$

—

 
Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

September 30, 2023

 

 

December 31, 2022

 

Accrued compensation

 

$

11,477

 

 

$

9,582

 

Accrued clinical trial expenses

 

 

4,236

 

 

 

12,262

 

Liability to collaboration partners

 

 

4,444

 

 

 

3,808

 

Accrued contract termination costs

 

 

2,624

 

 

 

3,902

 

Other accrued expenses

 

 

6,948

 

 

 

7,003

 

Total accrued expenses

 

$

29,729

 

 

$

36,557

 

 
Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2023 (in thousands):

 

 

 

Nine Months Ended September 30, 2023

 

 

 

2012 Purchase and Sale Agreement

 

 

2020 Purchase and Sale Agreement

 

 

Total

 

Liabilities related to the sales of future royalties, net – beginning balance

 

$

55,167

 

 

$

100,211

 

 

$

155,378

 

Non-cash royalty revenue

 

 

(28,035

)

 

 

(22,825

)

 

 

(50,860

)

Non-cash interest expense

 

 

3,551

 

 

 

14,916

 

 

 

18,467

 

Amortization of transaction costs

 

 

—

 

 

 

625

 

 

 

625

 

Liabilities related to the sales of future royalties, net – ending balance

 

$

30,683

 

 

$

92,927

 

 

$

123,610

 
Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

 

 

 

Foreign currency translation

 

 

Available-for-sale securities

 

 

Accumulated Other Comprehensive Income

 

Balance at December 31, 2022

 

$

(5,131

)

 

$

(1,776

)

 

$

(6,907

)

Foreign currency translation adjustments

 

 

139

 

 

 

—

 

 

 

139

 

Unrealized gain on available-for-sale securities

 

 

—

 

 

 

1,087

 

 

 

1,087

 

Balance at March 31, 2023

 

$

(4,992

)

 

$

(689

)

 

$

(5,681

)

Foreign currency translation adjustments

 

 

13

 

 

 

—

 

 

 

13

 

Unrealized gain on available-for-sale securities

 

 

—

 

 

 

244

 

 

 

244

 

Reclassification adjustments to income

 

 

(1,026

)

 

 

—

 

 

 

(1,026

)

Balance at June 30, 2023

 

$

(6,005

)

 

$

(445

)

 

$

(6,450

)

Foreign currency translation adjustments

 

 

(98

)

 

 

—

 

 

 

(98

)

Unrealized gain on available-for-sale securities

 

 

—

 

 

 

196

 

 

 

196

 

Balance at September 30, 2023

 

$

(6,103

)

 

$

(249

)

 

$

(6,352

)